Kapil Dhingra is the managing member of KAPital Consulting, LLC, a company he founded in 2008 that is dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize clinical and commercial advances in oncology. He is currently a member of the Board of Directors of LAVA Therapeutics B.V., Black Diamond Therapeutics, Inc., Median Technologies Inc., and Autolus Therapeutics plc. He has previously served on the Boards of several successful biotech companies, including Exosome Diagnostics, Five Prime Therapeutics Inc., Advanced Accelerator Applications S.A., Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics which were all acquired by major pharmaceutical companies.

From 1999 to 2008 Kapil Dhingra served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The University of Texas M.D. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine from 1997 to 1999, and at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008.

Kapil is board-certified in Internal Medicine and Medical Oncology. He serves as a member of the NCI Experimental Therapeutics panel, as well as the New Drug Advisory Committee of the EORTC.